Notices. Notice of availability; correction
249 words·~1 min read·
/register/2023/05/02/2023-09264·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2019-D-0362] A Risk-Based Approach to Monitoring of Clinical Investigations—Questions and Answers; Guidance for Industry; Correction AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability; correction. SUMMARY: The Food and Drug Administration
(FDA)is correcting a notice that appeared in the **Federal Register** of April 12, 2023. The document announced the availability of a final guidance entitled “A Risk-Based Approach to Monitoring of Clinical Investigations—Questions and Answers; Guidance for Industry.” The notice of availability for this final guidance was published with an incorrect OMB control number. This document corrects that error. FOR FURTHER INFORMATION CONTACT: Mona Shing, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 3355, Silver Spring, MD 20993-0002, 301-796-0910. SUPPLEMENTARY INFORMATION: In the **Federal Register** of April 12, 2023 (88 FR 22038), in FR Doc. 2023-07687, the following correction is made: 1. On page 22040, in the first column, in the last sentence of “II. Paperwork Reduction Act of 1995,” the OMB control number 0910-0733 is corrected to read: “. . .and the collections of information in FDA's guidance for industry entitled “Oversight of Clinical Investigations—A Risk-Based Approach to Monitoring” have been approved under OMB control number 0910-0014.” The correction changes the OMB control number from a number that was discontinued to an active one. Dated: April 27, 2023. Lauren K. Roth, Associate Commissioner for Policy. [FR Doc. 2023-09264 Filed 5-1-23; 8:45 am]